Abstract 974: New target discovery for oncology utilizing phenotypic selection and primary NSCLC patient tumors

Abstract

Abstract Lung cancer is the most common type of cancer, with approximately 222,000 new cases expected each year in the United States. Approximately 72% of the individuals diagnosed with lung cancer will fall victim to the disease. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, but current treatments will not cure the disease for most patients. In an effort to identify novel therapeutics to address this unmet need, a phenotypic screening campaign was initiated. This type of target identification approach allows the discovery of novel drug targets by selection of antibodies based on their ability to elicit a specific desired phenotype. Once antibodies with the desired function are isolated, the targets to which the “hit” antibodies bind can be identified using a variety of approaches including IP-mass spec. Although phenotypic screens have been performed previously, the current effort has important advantages over those described previously. Specifically, this included the use of several unique screening assays run in parallel to allow the evaluation of multiple phenotypes simultaneously. Also unique was the use of primary material from NSCLC patients for both selection and functional screening. Specifically, we demonstrate the use of primary tumor cells in high throughput screening assays. We show the utility of incorporating novel screening assays including anoikis and spheroids with multiple endpoint readouts. Finally we provide data describing a series of “hit” antibodies isolated in the screen which had a variety of activities across the screening assays. These studies show the utility of function-first screening in the identification of unique potential therapeutic targets for oncology. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 974. doi:1538-7445.AM2012-974